Suppr超能文献

碳酸酐酶的变化可能是高血压代谢改变的初始步骤。

Changes in carbonic anhydrase may be the initial step of altered metabolism in hypertension.

作者信息

Parui R, Gambhir K K, Mehrotra P P

机构信息

Department of Medicine, College of Medicine, Howard University, Washington, D.C. 20059.

出版信息

Biochem Int. 1991 Mar;23(4):779-89.

PMID:1908243
Abstract

Carbonic anhydrase (CA) is a well characterized pH regulatory enzyme in most of the tissues in the body. Changes in activities of CA have been associated with altered metabolism, especially in diabetes mellitus. Insulin resistance and hyperinsulinemia are common in hypertension. To investigate the possible role of CA, we measured the CA activity spectrophotometrically using p-nitrophenyl acetate as a substrate and acetazolamide, the specific inhibitor, in erythrocytes from normotensive and essential hypertensive subjects. Further, to evaluate the insulin action on CA, we used two different hemolysates; (i) insulin applied into hemolysate and (ii) hemolysate from insulin treated erythrocytes in vitro before the determination of CA activity. Two different levels of CA activities were obtained in these patients. CA activities were much lower (mean +/- SD, 0.88 +/- 0.19 U/min/mL) and higher (mean +/- SD, 1.77 +/- 0.23 U/min/mL) in patients than the normotensive controls (mean +/- 1 SD, 1.41 +/- 0.1 U/min/mL). These differences in both the groups were statistically significant (p less than 0.001). Similarly, total esterase activities in patients were (1.41 +/- 0.27 U/min/mL) that was 30% less in low activity group and (2.47 +/- 0.25 U/min/mL) that was 22% more in higher activity group in comparison with those from normotensives (2.02 +/- 0.17 U/min/mL). The relative percent of CA activities of insulin treated erythrocytes from normotensives and hypertensives were 11% and 18% higher than without insulin (p less than 0.05). No difference was observed when insulin was applied in the hemolysate. We conclude that essential hypertensive patients are associated with altered CA activity.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

碳酸酐酶(CA)是体内大多数组织中一种特征明确的pH调节酶。CA活性的变化与代谢改变有关,尤其是在糖尿病中。胰岛素抵抗和高胰岛素血症在高血压中很常见。为了研究CA的可能作用,我们使用对硝基苯乙酸作为底物,通过分光光度法测量了正常血压和原发性高血压患者红细胞中CA的活性,并使用了特异性抑制剂乙酰唑胺。此外,为了评估胰岛素对CA的作用,我们使用了两种不同的溶血产物:(i)将胰岛素加入溶血产物中;(ii)在测定CA活性之前,使用体外经胰岛素处理的红细胞的溶血产物。在这些患者中获得了两种不同水平的CA活性。患者的CA活性比正常血压对照组(平均值±1标准差,1.41±0.1 U/分钟/毫升)低得多(平均值±标准差,0.88±0.19 U/分钟/毫升)和高得多(平均值±标准差,1.77±0.23 U/分钟/毫升)。两组之间的这些差异具有统计学意义(p小于0.001)。同样,与正常血压者(2.02±0.17 U/分钟/毫升)相比,患者的总酯酶活性在低活性组中为(1.41±0.27 U/分钟/毫升),低30%,在高活性组中为(2.47±0.25 U/分钟/毫升),高22%。正常血压者和高血压患者经胰岛素处理的红细胞的CA活性相对百分比分别比未加胰岛素时高11%和18%(p小于0.05)。当将胰岛素加入溶血产物中时未观察到差异。我们得出结论,原发性高血压患者与CA活性改变有关。(摘要截短于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验